nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—H1F0—hematologic cancer	0.302	0.906	CbGaD
Haloperidol—ABCB1—hematologic cancer	0.0312	0.0936	CbGaD
Haloperidol—CBR1—Doxorubicin—hematologic cancer	0.0252	0.06	CbGbCtD
Haloperidol—UGT1A9—Irinotecan—hematologic cancer	0.0116	0.0277	CbGbCtD
Haloperidol—CYP1A2—Anagrelide—hematologic cancer	0.0111	0.0264	CbGbCtD
Haloperidol—CYP1A1—Methoxsalen—hematologic cancer	0.0111	0.0264	CbGbCtD
Haloperidol—CYP1A1—Bortezomib—hematologic cancer	0.0106	0.0251	CbGbCtD
Haloperidol—CYP1A1—Daunorubicin—hematologic cancer	0.0101	0.024	CbGbCtD
Haloperidol—CYP1A1—Thalidomide—hematologic cancer	0.0092	0.0219	CbGbCtD
Haloperidol—CYP1A1—Dacarbazine—hematologic cancer	0.00791	0.0188	CbGbCtD
Haloperidol—CYP2C9—Bexarotene—hematologic cancer	0.00693	0.0165	CbGbCtD
Haloperidol—ABCB1—Lenalidomide—hematologic cancer	0.00673	0.016	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.00648	0.0154	CbGbCtD
Haloperidol—CYP3A7—Ifosfamide—hematologic cancer	0.00648	0.0154	CbGbCtD
Haloperidol—CYP1A1—Dasatinib—hematologic cancer	0.00621	0.0148	CbGbCtD
Haloperidol—CYP3A7—Imatinib—hematologic cancer	0.00619	0.0147	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.00619	0.0147	CbGbCtD
Haloperidol—CYP3A5—Daunorubicin—hematologic cancer	0.00606	0.0144	CbGbCtD
Haloperidol—CYP2D6—Lomustine—hematologic cancer	0.00589	0.014	CbGbCtD
Haloperidol—CYP1A2—Carmustine—hematologic cancer	0.00583	0.0139	CbGbCtD
Haloperidol—CYP2C9—Idarubicin—hematologic cancer	0.00574	0.0137	CbGbCtD
Haloperidol—CYP3A5—Thalidomide—hematologic cancer	0.00552	0.0131	CbGbCtD
Haloperidol—CYP3A5—Teniposide—hematologic cancer	0.00527	0.0125	CbGbCtD
Haloperidol—CYP2D6—Idarubicin—hematologic cancer	0.00525	0.0125	CbGbCtD
Haloperidol—CYP2C19—Bortezomib—hematologic cancer	0.00511	0.0122	CbGbCtD
Haloperidol—CYP1A2—Methoxsalen—hematologic cancer	0.00496	0.0118	CbGbCtD
Haloperidol—CYP3A5—Ifosfamide—hematologic cancer	0.00486	0.0116	CbGbCtD
Haloperidol—CYP1A2—Bortezomib—hematologic cancer	0.00472	0.0112	CbGbCtD
Haloperidol—CYP3A5—Imatinib—hematologic cancer	0.00464	0.011	CbGbCtD
Haloperidol—CYP1A2—Daunorubicin—hematologic cancer	0.00451	0.0107	CbGbCtD
Haloperidol—CYP2D6—Hydroxyurea—hematologic cancer	0.00447	0.0106	CbGbCtD
Haloperidol—CYP2C19—Thalidomide—hematologic cancer	0.00445	0.0106	CbGbCtD
Haloperidol—CYP1A2—Alitretinoin—hematologic cancer	0.00442	0.0105	CbGbCtD
Haloperidol—CYP2C9—Bortezomib—hematologic cancer	0.00425	0.0101	CbGbCtD
Haloperidol—CYP2C19—Teniposide—hematologic cancer	0.00425	0.0101	CbGbCtD
Haloperidol—CYP1A2—Thalidomide—hematologic cancer	0.00411	0.00978	CbGbCtD
Haloperidol—CYP3A4—Bexarotene—hematologic cancer	0.00403	0.00959	CbGbCtD
Haloperidol—ABCB1—Daunorubicin—hematologic cancer	0.00394	0.00939	CbGbCtD
Haloperidol—CYP2C19—Ifosfamide—hematologic cancer	0.00392	0.00933	CbGbCtD
Haloperidol—CYP2D6—Bortezomib—hematologic cancer	0.00389	0.00925	CbGbCtD
Haloperidol—CYP3A7—Irinotecan—hematologic cancer	0.00387	0.0092	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00387	0.0092	CbGbCtD
Haloperidol—ABCB1—Alitretinoin—hematologic cancer	0.00386	0.0092	CbGbCtD
Haloperidol—CYP3A4—Busulfan—hematologic cancer	0.00375	0.00892	CbGbCtD
Haloperidol—CYP3A4—Lomustine—hematologic cancer	0.00375	0.00892	CbGbCtD
Haloperidol—CYP2C19—Imatinib—hematologic cancer	0.00374	0.00891	CbGbCtD
Haloperidol—CYP3A5—Dasatinib—hematologic cancer	0.00373	0.00887	CbGbCtD
Haloperidol—CYP2C9—Thalidomide—hematologic cancer	0.0037	0.00881	CbGbCtD
Haloperidol—CYP1A2—Dacarbazine—hematologic cancer	0.00353	0.00841	CbGbCtD
Haloperidol—CYP2C9—Teniposide—hematologic cancer	0.00353	0.0084	CbGbCtD
Haloperidol—CYP1A2—Imatinib—hematologic cancer	0.00346	0.00822	CbGbCtD
Haloperidol—CYP3A7—Vincristine—hematologic cancer	0.00338	0.00804	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.00338	0.00804	CbGbCtD
Haloperidol—CYP3A4—Thiotepa—hematologic cancer	0.00334	0.00795	CbGbCtD
Haloperidol—CYP2C9—Ifosfamide—hematologic cancer	0.00326	0.00776	CbGbCtD
Haloperidol—CYP1A1—Dexamethasone—hematologic cancer	0.00318	0.00757	CbGbCtD
Haloperidol—CYP2C9—Imatinib—hematologic cancer	0.00311	0.00741	CbGbCtD
Haloperidol—ABCB1—Imatinib—hematologic cancer	0.00302	0.00719	CbGbCtD
Haloperidol—CYP3A5—Irinotecan—hematologic cancer	0.0029	0.0069	CbGbCtD
Haloperidol—CYP2D6—Imatinib—hematologic cancer	0.00285	0.00677	CbGbCtD
Haloperidol—CYP2C9—Nilotinib—hematologic cancer	0.00283	0.00673	CbGbCtD
Haloperidol—CYP1A2—Dasatinib—hematologic cancer	0.00278	0.0066	CbGbCtD
Haloperidol—ABCB1—Nilotinib—hematologic cancer	0.00275	0.00653	CbGbCtD
Haloperidol—ABCB1—Vinorelbine—hematologic cancer	0.00272	0.00648	CbGbCtD
Haloperidol—CYP3A4—Methoxsalen—hematologic cancer	0.0026	0.00618	CbGbCtD
Haloperidol—CYP2D6—Nilotinib—hematologic cancer	0.00259	0.00616	CbGbCtD
Haloperidol—CYP2D6—Vinorelbine—hematologic cancer	0.00257	0.0061	CbGbCtD
Haloperidol—CYP3A7—Dexamethasone—hematologic cancer	0.00255	0.00606	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00255	0.00606	CbGbCtD
Haloperidol—CYP3A5—Vincristine—hematologic cancer	0.00253	0.00603	CbGbCtD
Haloperidol—CYP3A4—Bortezomib—hematologic cancer	0.00247	0.00588	CbGbCtD
Haloperidol—CYP2C19—Prednisone—hematologic cancer	0.00247	0.00587	CbGbCtD
Haloperidol—ABCB1—Dasatinib—hematologic cancer	0.00243	0.00577	CbGbCtD
Haloperidol—ABCB1—Mitoxantrone—hematologic cancer	0.0024	0.0057	CbGbCtD
Haloperidol—CYP3A4—Daunorubicin—hematologic cancer	0.00236	0.00562	CbGbCtD
Haloperidol—CYP3A5—Etoposide—hematologic cancer	0.00232	0.00553	CbGbCtD
Haloperidol—ABCB1—Betamethasone—hematologic cancer	0.00214	0.00508	CbGbCtD
Haloperidol—ABCB1—Gemcitabine—hematologic cancer	0.00212	0.00504	CbGbCtD
Haloperidol—ABCB1—Prednisolone—hematologic cancer	0.00211	0.00502	CbGbCtD
Haloperidol—CYP3A4—Cytarabine—hematologic cancer	0.00208	0.00496	CbGbCtD
Haloperidol—CYP3A4—Teniposide—hematologic cancer	0.00205	0.00489	CbGbCtD
Haloperidol—ABCB1—Prednisone—hematologic cancer	0.00199	0.00474	CbGbCtD
Haloperidol—CYP3A5—Dexamethasone—hematologic cancer	0.00191	0.00454	CbGbCtD
Haloperidol—CYP3A4—Ifosfamide—hematologic cancer	0.0019	0.00451	CbGbCtD
Haloperidol—ABCB1—Irinotecan—hematologic cancer	0.00189	0.00449	CbGbCtD
Haloperidol—CYP3A4—Imatinib—hematologic cancer	0.00181	0.00431	CbGbCtD
Haloperidol—CYP1A2—Etoposide—hematologic cancer	0.00173	0.00411	CbGbCtD
Haloperidol—CYP3A4—Ruxolitinib—hematologic cancer	0.0017	0.00406	CbGbCtD
Haloperidol—ABCB1—Vinblastine—hematologic cancer	0.00168	0.00399	CbGbCtD
Haloperidol—ABCB1—Vincristine—hematologic cancer	0.00165	0.00393	CbGbCtD
Haloperidol—CYP3A4—Nilotinib—hematologic cancer	0.00165	0.00391	CbGbCtD
Haloperidol—CYP3A4—Vinorelbine—hematologic cancer	0.00163	0.00388	CbGbCtD
Haloperidol—CYP2C9—Cisplatin—hematologic cancer	0.00159	0.00377	CbGbCtD
Haloperidol—CYP2D6—Vinblastine—hematologic cancer	0.00158	0.00376	CbGbCtD
Haloperidol—CYP2C19—Dexamethasone—hematologic cancer	0.00154	0.00367	CbGbCtD
Haloperidol—ABCB1—Cisplatin—hematologic cancer	0.00154	0.00366	CbGbCtD
Haloperidol—ABCB1—Etoposide—hematologic cancer	0.00151	0.0036	CbGbCtD
Haloperidol—CYP3A4—Triamcinolone—hematologic cancer	0.00149	0.00355	CbGbCtD
Haloperidol—CYP3A4—Dasatinib—hematologic cancer	0.00145	0.00346	CbGbCtD
Haloperidol—CYP3A4—Mitoxantrone—hematologic cancer	0.00144	0.00342	CbGbCtD
Haloperidol—CYP2C9—Dexamethasone—hematologic cancer	0.00128	0.00305	CbGbCtD
Haloperidol—CYP3A4—Betamethasone—hematologic cancer	0.00128	0.00305	CbGbCtD
Haloperidol—CYP3A4—Prednisolone—hematologic cancer	0.00126	0.00301	CbGbCtD
Haloperidol—ABCB1—Dexamethasone—hematologic cancer	0.00124	0.00296	CbGbCtD
Haloperidol—CYP3A4—Prednisone—hematologic cancer	0.00119	0.00284	CbGbCtD
Haloperidol—CYP2D6—Dexamethasone—hematologic cancer	0.00117	0.00279	CbGbCtD
Haloperidol—CYP3A4—Irinotecan—hematologic cancer	0.00113	0.00269	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—hematologic cancer	0.00103	0.00245	CbGbCtD
Haloperidol—CYP3A4—Vinblastine—hematologic cancer	0.00101	0.00239	CbGbCtD
Haloperidol—ABCB1—Methotrexate—hematologic cancer	0.000999	0.00238	CbGbCtD
Haloperidol—CYP3A4—Vincristine—hematologic cancer	0.000988	0.00235	CbGbCtD
Haloperidol—CYP2D6—Doxorubicin—hematologic cancer	0.000971	0.00231	CbGbCtD
Haloperidol—CYP3A4—Etoposide—hematologic cancer	0.000906	0.00216	CbGbCtD
Haloperidol—DRD4—testis—hematologic cancer	0.000783	0.0412	CbGeAlD
Haloperidol—CYP3A4—Dexamethasone—hematologic cancer	0.000745	0.00177	CbGbCtD
Haloperidol—H1F0—hematopoietic system—hematologic cancer	0.000728	0.0383	CbGeAlD
Haloperidol—CBR1—gonad—hematologic cancer	0.000676	0.0356	CbGeAlD
Haloperidol—CYP3A4—Doxorubicin—hematologic cancer	0.000618	0.00147	CbGbCtD
Haloperidol—CBR1—blood—hematologic cancer	0.000589	0.031	CbGeAlD
Haloperidol—CBR1—bone marrow—hematologic cancer	0.00057	0.03	CbGeAlD
Haloperidol—H1F0—gonad—hematologic cancer	0.000554	0.0292	CbGeAlD
Haloperidol—CBR1—lung—hematologic cancer	0.000516	0.0272	CbGeAlD
Haloperidol—CBR1—testis—hematologic cancer	0.000487	0.0256	CbGeAlD
Haloperidol—H1F0—blood—hematologic cancer	0.000483	0.0254	CbGeAlD
Haloperidol—H1F0—bone marrow—hematologic cancer	0.000467	0.0246	CbGeAlD
Haloperidol—CYP2C19—hematopoietic system—hematologic cancer	0.000439	0.0231	CbGeAlD
Haloperidol—H1F0—lung—hematologic cancer	0.000423	0.0223	CbGeAlD
Haloperidol—KCNH2—hematopoietic system—hematologic cancer	0.000419	0.022	CbGeAlD
Haloperidol—H1F0—testis—hematologic cancer	0.000399	0.021	CbGeAlD
Haloperidol—CYP1A2—hematopoietic system—hematologic cancer	0.000358	0.0189	CbGeAlD
Haloperidol—CYP1A1—hematopoietic system—hematologic cancer	0.000354	0.0186	CbGeAlD
Haloperidol—CBR1—lymph node—hematologic cancer	0.000353	0.0186	CbGeAlD
Haloperidol—SIGMAR1—blood—hematologic cancer	0.000348	0.0183	CbGeAlD
Haloperidol—HTR2B—blood—hematologic cancer	0.000348	0.0183	CbGeAlD
Haloperidol—CYP3A5—hematopoietic system—hematologic cancer	0.000346	0.0182	CbGeAlD
Haloperidol—CYP2C9—hematopoietic system—hematologic cancer	0.00034	0.0179	CbGeAlD
Haloperidol—SIGMAR1—bone marrow—hematologic cancer	0.000337	0.0178	CbGeAlD
Haloperidol—HRH1—hematopoietic system—hematologic cancer	0.000336	0.0177	CbGeAlD
Haloperidol—CBR1—Vincristine—Vinorelbine—hematologic cancer	0.000314	0.14	CbGdCrCtD
Haloperidol—SIGMAR1—lung—hematologic cancer	0.000305	0.0161	CbGeAlD
Haloperidol—HTR2B—lung—hematologic cancer	0.000305	0.016	CbGeAlD
Haloperidol—CYP2C19—blood—hematologic cancer	0.000291	0.0153	CbGeAlD
Haloperidol—H1F0—lymph node—hematologic cancer	0.000289	0.0152	CbGeAlD
Haloperidol—SIGMAR1—testis—hematologic cancer	0.000288	0.0152	CbGeAlD
Haloperidol—HTR2A—hematopoietic system—hematologic cancer	0.00028	0.0148	CbGeAlD
Haloperidol—KCNH2—blood—hematologic cancer	0.000277	0.0146	CbGeAlD
Haloperidol—KCNH2—bone marrow—hematologic cancer	0.000268	0.0141	CbGeAlD
Haloperidol—CYP3A4—hematopoietic system—hematologic cancer	0.000259	0.0137	CbGeAlD
Haloperidol—CYP2D6—hematopoietic system—hematologic cancer	0.000255	0.0134	CbGeAlD
Haloperidol—CBR1—Vincristine—Vinblastine—hematologic cancer	0.000251	0.112	CbGdCrCtD
Haloperidol—DRD2—lung—hematologic cancer	0.000247	0.013	CbGeAlD
Haloperidol—CYP1A2—blood—hematologic cancer	0.000237	0.0125	CbGeAlD
Haloperidol—CYP1A1—blood—hematologic cancer	0.000234	0.0123	CbGeAlD
Haloperidol—DRD2—testis—hematologic cancer	0.000233	0.0123	CbGeAlD
Haloperidol—KCNH2—testis—hematologic cancer	0.000229	0.0121	CbGeAlD
Haloperidol—CYP3A5—blood—hematologic cancer	0.000229	0.0121	CbGeAlD
Haloperidol—CYP2C9—blood—hematologic cancer	0.000225	0.0119	CbGeAlD
Haloperidol—HTR2A—gonad—hematologic cancer	0.000213	0.0112	CbGeAlD
Haloperidol—SIGMAR1—lymph node—hematologic cancer	0.000209	0.011	CbGeAlD
Haloperidol—HTR2B—lymph node—hematologic cancer	0.000208	0.011	CbGeAlD
Haloperidol—CYP1A2—lung—hematologic cancer	0.000208	0.011	CbGeAlD
Haloperidol—CYP1A1—lung—hematologic cancer	0.000205	0.0108	CbGeAlD
Haloperidol—CYP3A5—lung—hematologic cancer	0.000201	0.0106	CbGeAlD
Haloperidol—HRH1—lung—hematologic cancer	0.000195	0.0103	CbGeAlD
Haloperidol—CBR1—Azacitidine—Pentostatin—hematologic cancer	0.000191	0.0853	CbGdCrCtD
Haloperidol—HTR2A—blood—hematologic cancer	0.000186	0.00977	CbGeAlD
Haloperidol—HRH1—testis—hematologic cancer	0.000184	0.00968	CbGeAlD
Haloperidol—ABCB1—hematopoietic system—hematologic cancer	0.000184	0.00967	CbGeAlD
Haloperidol—CYP3A4—blood—hematologic cancer	0.000172	0.00905	CbGeAlD
Haloperidol—CBR1—Azacitidine—Clofarabine—hematologic cancer	0.00017	0.076	CbGdCrCtD
Haloperidol—CYP2D6—blood—hematologic cancer	0.000169	0.0089	CbGeAlD
Haloperidol—KCNH2—lymph node—hematologic cancer	0.000166	0.00875	CbGeAlD
Haloperidol—HTR2A—lung—hematologic cancer	0.000163	0.00857	CbGeAlD
Haloperidol—CBR1—Azacitidine—Nelarabine—hematologic cancer	0.00016	0.0715	CbGdCrCtD
Haloperidol—HTR2A—testis—hematologic cancer	0.000154	0.00809	CbGeAlD
Haloperidol—CYP1A1—lymph node—hematologic cancer	0.00014	0.00739	CbGeAlD
Haloperidol—CYP2D6—testis—hematologic cancer	0.00014	0.00737	CbGeAlD
Haloperidol—ABCB1—gonad—hematologic cancer	0.00014	0.00735	CbGeAlD
Haloperidol—HRH1—lymph node—hematologic cancer	0.000133	0.00702	CbGeAlD
Haloperidol—EBP—Azacitidine—Pentostatin—hematologic cancer	0.00013	0.058	CbGdCrCtD
Haloperidol—CBR1—Azacitidine—Fludarabine—hematologic cancer	0.000125	0.0558	CbGdCrCtD
Haloperidol—ABCB1—blood—hematologic cancer	0.000122	0.00641	CbGeAlD
Haloperidol—CBR1—Azacitidine—Cytarabine—hematologic cancer	0.000118	0.0527	CbGdCrCtD
Haloperidol—CBR1—Azacitidine—Gemcitabine—hematologic cancer	0.000118	0.0527	CbGdCrCtD
Haloperidol—ABCB1—bone marrow—hematologic cancer	0.000118	0.0062	CbGeAlD
Haloperidol—EBP—Azacitidine—Clofarabine—hematologic cancer	0.000116	0.0517	CbGdCrCtD
Haloperidol—CBR1—Azacitidine—Cladribine—hematologic cancer	0.000115	0.0514	CbGdCrCtD
Haloperidol—EBP—Azacitidine—Nelarabine—hematologic cancer	0.000109	0.0486	CbGdCrCtD
Haloperidol—ABCB1—lung—hematologic cancer	0.000107	0.00562	CbGeAlD
Haloperidol—ABCB1—testis—hematologic cancer	0.000101	0.0053	CbGeAlD
Haloperidol—EBP—Azacitidine—Fludarabine—hematologic cancer	8.51e-05	0.038	CbGdCrCtD
Haloperidol—EBP—Azacitidine—Cytarabine—hematologic cancer	8.04e-05	0.0359	CbGdCrCtD
Haloperidol—EBP—Azacitidine—Gemcitabine—hematologic cancer	8.04e-05	0.0359	CbGdCrCtD
Haloperidol—EBP—Azacitidine—Cladribine—hematologic cancer	7.83e-05	0.0349	CbGdCrCtD
Haloperidol—ABCB1—lymph node—hematologic cancer	7.3e-05	0.00384	CbGeAlD
Haloperidol—Hypotension—Betamethasone—hematologic cancer	2.19e-05	0.000146	CcSEcCtD
Haloperidol—Hypotension—Dexamethasone—hematologic cancer	2.19e-05	0.000146	CcSEcCtD
Haloperidol—Nausea—Carmustine—hematologic cancer	2.19e-05	0.000146	CcSEcCtD
Haloperidol—Angiopathy—Methotrexate—hematologic cancer	2.18e-05	0.000145	CcSEcCtD
Haloperidol—Vomiting—Mitoxantrone—hematologic cancer	2.18e-05	0.000145	CcSEcCtD
Haloperidol—Vomiting—Irinotecan—hematologic cancer	2.18e-05	0.000145	CcSEcCtD
Haloperidol—Immune system disorder—Methotrexate—hematologic cancer	2.17e-05	0.000145	CcSEcCtD
Haloperidol—Nausea—Alitretinoin—hematologic cancer	2.17e-05	0.000145	CcSEcCtD
Haloperidol—Convulsion—Prednisone—hematologic cancer	2.17e-05	0.000145	CcSEcCtD
Haloperidol—Visual impairment—Epirubicin—hematologic cancer	2.17e-05	0.000145	CcSEcCtD
Haloperidol—Mediastinal disorder—Methotrexate—hematologic cancer	2.17e-05	0.000144	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—hematologic cancer	2.16e-05	0.000144	CcSEcCtD
Haloperidol—Hypertension—Prednisone—hematologic cancer	2.16e-05	0.000144	CcSEcCtD
Haloperidol—Rash—Irinotecan—hematologic cancer	2.16e-05	0.000144	CcSEcCtD
Haloperidol—Rash—Mitoxantrone—hematologic cancer	2.16e-05	0.000144	CcSEcCtD
Haloperidol—Dermatitis—Mitoxantrone—hematologic cancer	2.16e-05	0.000144	CcSEcCtD
Haloperidol—Dermatitis—Irinotecan—hematologic cancer	2.16e-05	0.000144	CcSEcCtD
Haloperidol—Headache—Irinotecan—hematologic cancer	2.15e-05	0.000143	CcSEcCtD
Haloperidol—Headache—Mitoxantrone—hematologic cancer	2.15e-05	0.000143	CcSEcCtD
Haloperidol—Nausea—Ifosfamide—hematologic cancer	2.14e-05	0.000143	CcSEcCtD
Haloperidol—Feeling abnormal—Triamcinolone—hematologic cancer	2.13e-05	0.000142	CcSEcCtD
Haloperidol—Diarrhoea—Cisplatin—hematologic cancer	2.13e-05	0.000142	CcSEcCtD
Haloperidol—Anxiety—Prednisone—hematologic cancer	2.12e-05	0.000142	CcSEcCtD
Haloperidol—Alopecia—Methotrexate—hematologic cancer	2.12e-05	0.000142	CcSEcCtD
Haloperidol—Vomiting—Gemcitabine—hematologic cancer	2.12e-05	0.000142	CcSEcCtD
Haloperidol—Insomnia—Dexamethasone—hematologic cancer	2.12e-05	0.000142	CcSEcCtD
Haloperidol—Insomnia—Betamethasone—hematologic cancer	2.12e-05	0.000142	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	2.12e-05	0.000141	CcSEcCtD
Haloperidol—Mental disorder—Methotrexate—hematologic cancer	2.11e-05	0.00014	CcSEcCtD
Haloperidol—Rash—Gemcitabine—hematologic cancer	2.11e-05	0.00014	CcSEcCtD
Haloperidol—Dermatitis—Gemcitabine—hematologic cancer	2.1e-05	0.00014	CcSEcCtD
Haloperidol—Eye disorder—Epirubicin—hematologic cancer	2.1e-05	0.00014	CcSEcCtD
Haloperidol—Hypersensitivity—Etoposide—hematologic cancer	2.1e-05	0.00014	CcSEcCtD
Haloperidol—Malnutrition—Methotrexate—hematologic cancer	2.09e-05	0.00014	CcSEcCtD
Haloperidol—Headache—Gemcitabine—hematologic cancer	2.09e-05	0.00014	CcSEcCtD
Haloperidol—Nausea—Vincristine—hematologic cancer	2.09e-05	0.000139	CcSEcCtD
Haloperidol—Cardiac disorder—Epirubicin—hematologic cancer	2.09e-05	0.000139	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—hematologic cancer	2.08e-05	0.000139	CcSEcCtD
Haloperidol—Hypersensitivity—Prednisolone—hematologic cancer	2.07e-05	0.000138	CcSEcCtD
Haloperidol—Dyspepsia—Betamethasone—hematologic cancer	2.07e-05	0.000138	CcSEcCtD
Haloperidol—Dyspepsia—Dexamethasone—hematologic cancer	2.07e-05	0.000138	CcSEcCtD
Haloperidol—Urinary tract disorder—Doxorubicin—hematologic cancer	2.06e-05	0.000137	CcSEcCtD
Haloperidol—Urticaria—Triamcinolone—hematologic cancer	2.05e-05	0.000137	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—hematologic cancer	2.05e-05	0.000136	CcSEcCtD
Haloperidol—Body temperature increased—Triamcinolone—hematologic cancer	2.04e-05	0.000136	CcSEcCtD
Haloperidol—Anaphylactic shock—Prednisone—hematologic cancer	2.04e-05	0.000136	CcSEcCtD
Haloperidol—Oedema—Prednisone—hematologic cancer	2.04e-05	0.000136	CcSEcCtD
Haloperidol—Angiopathy—Epirubicin—hematologic cancer	2.04e-05	0.000136	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—hematologic cancer	2.04e-05	0.000136	CcSEcCtD
Haloperidol—Decreased appetite—Dexamethasone—hematologic cancer	2.04e-05	0.000136	CcSEcCtD
Haloperidol—Decreased appetite—Betamethasone—hematologic cancer	2.04e-05	0.000136	CcSEcCtD
Haloperidol—Nausea—Irinotecan—hematologic cancer	2.04e-05	0.000136	CcSEcCtD
Haloperidol—Nausea—Mitoxantrone—hematologic cancer	2.04e-05	0.000136	CcSEcCtD
Haloperidol—Immune system disorder—Epirubicin—hematologic cancer	2.03e-05	0.000136	CcSEcCtD
Haloperidol—Mediastinal disorder—Epirubicin—hematologic cancer	2.03e-05	0.000135	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.03e-05	0.000135	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.03e-05	0.000135	CcSEcCtD
Haloperidol—Pruritus—Etoposide—hematologic cancer	2.02e-05	0.000135	CcSEcCtD
Haloperidol—Visual impairment—Doxorubicin—hematologic cancer	2.01e-05	0.000134	CcSEcCtD
Haloperidol—Nervous system disorder—Prednisone—hematologic cancer	2e-05	0.000134	CcSEcCtD
Haloperidol—Tachycardia—Prednisone—hematologic cancer	1.99e-05	0.000133	CcSEcCtD
Haloperidol—Alopecia—Epirubicin—hematologic cancer	1.99e-05	0.000133	CcSEcCtD
Haloperidol—Skin disorder—Prednisone—hematologic cancer	1.99e-05	0.000132	CcSEcCtD
Haloperidol—Nausea—Gemcitabine—hematologic cancer	1.98e-05	0.000132	CcSEcCtD
Haloperidol—Vomiting—Cisplatin—hematologic cancer	1.98e-05	0.000132	CcSEcCtD
Haloperidol—Hyperhidrosis—Prednisone—hematologic cancer	1.98e-05	0.000132	CcSEcCtD
Haloperidol—Vision blurred—Methotrexate—hematologic cancer	1.97e-05	0.000132	CcSEcCtD
Haloperidol—Mental disorder—Epirubicin—hematologic cancer	1.97e-05	0.000131	CcSEcCtD
Haloperidol—Rash—Cisplatin—hematologic cancer	1.96e-05	0.000131	CcSEcCtD
Haloperidol—Dermatitis—Cisplatin—hematologic cancer	1.96e-05	0.000131	CcSEcCtD
Haloperidol—Malnutrition—Epirubicin—hematologic cancer	1.96e-05	0.000131	CcSEcCtD
Haloperidol—Diarrhoea—Etoposide—hematologic cancer	1.95e-05	0.00013	CcSEcCtD
Haloperidol—Anorexia—Prednisone—hematologic cancer	1.95e-05	0.00013	CcSEcCtD
Haloperidol—Eye disorder—Doxorubicin—hematologic cancer	1.95e-05	0.00013	CcSEcCtD
Haloperidol—Anaemia—Methotrexate—hematologic cancer	1.93e-05	0.000129	CcSEcCtD
Haloperidol—Feeling abnormal—Dexamethasone—hematologic cancer	1.93e-05	0.000129	CcSEcCtD
Haloperidol—Feeling abnormal—Betamethasone—hematologic cancer	1.93e-05	0.000129	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—hematologic cancer	1.93e-05	0.000129	CcSEcCtD
Haloperidol—Hypersensitivity—Triamcinolone—hematologic cancer	1.91e-05	0.000127	CcSEcCtD
Haloperidol—Angiopathy—Doxorubicin—hematologic cancer	1.89e-05	0.000126	CcSEcCtD
Haloperidol—Dizziness—Etoposide—hematologic cancer	1.89e-05	0.000126	CcSEcCtD
Haloperidol—Muscle spasms—Epirubicin—hematologic cancer	1.88e-05	0.000126	CcSEcCtD
Haloperidol—Immune system disorder—Doxorubicin—hematologic cancer	1.88e-05	0.000125	CcSEcCtD
Haloperidol—Vertigo—Methotrexate—hematologic cancer	1.88e-05	0.000125	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—hematologic cancer	1.88e-05	0.000125	CcSEcCtD
Haloperidol—Leukopenia—Methotrexate—hematologic cancer	1.87e-05	0.000125	CcSEcCtD
Haloperidol—Urticaria—Dexamethasone—hematologic cancer	1.86e-05	0.000124	CcSEcCtD
Haloperidol—Urticaria—Betamethasone—hematologic cancer	1.86e-05	0.000124	CcSEcCtD
Haloperidol—Dizziness—Prednisolone—hematologic cancer	1.86e-05	0.000124	CcSEcCtD
Haloperidol—Body temperature increased—Dexamethasone—hematologic cancer	1.86e-05	0.000124	CcSEcCtD
Haloperidol—Body temperature increased—Betamethasone—hematologic cancer	1.86e-05	0.000124	CcSEcCtD
Haloperidol—Nausea—Cisplatin—hematologic cancer	1.85e-05	0.000123	CcSEcCtD
Haloperidol—Insomnia—Prednisone—hematologic cancer	1.85e-05	0.000123	CcSEcCtD
Haloperidol—Vision blurred—Epirubicin—hematologic cancer	1.85e-05	0.000123	CcSEcCtD
Haloperidol—Alopecia—Doxorubicin—hematologic cancer	1.84e-05	0.000123	CcSEcCtD
Haloperidol—Pruritus—Triamcinolone—hematologic cancer	1.83e-05	0.000122	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—hematologic cancer	1.82e-05	0.000122	CcSEcCtD
Haloperidol—Convulsion—Methotrexate—hematologic cancer	1.81e-05	0.000121	CcSEcCtD
Haloperidol—Vomiting—Etoposide—hematologic cancer	1.81e-05	0.000121	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—hematologic cancer	1.81e-05	0.000121	CcSEcCtD
Haloperidol—Anaemia—Epirubicin—hematologic cancer	1.81e-05	0.000121	CcSEcCtD
Haloperidol—Agitation—Epirubicin—hematologic cancer	1.8e-05	0.00012	CcSEcCtD
Haloperidol—Dyspepsia—Prednisone—hematologic cancer	1.8e-05	0.00012	CcSEcCtD
Haloperidol—Rash—Etoposide—hematologic cancer	1.8e-05	0.00012	CcSEcCtD
Haloperidol—Dermatitis—Etoposide—hematologic cancer	1.8e-05	0.00012	CcSEcCtD
Haloperidol—Headache—Etoposide—hematologic cancer	1.79e-05	0.000119	CcSEcCtD
Haloperidol—Decreased appetite—Prednisone—hematologic cancer	1.78e-05	0.000118	CcSEcCtD
Haloperidol—Rash—Prednisolone—hematologic cancer	1.77e-05	0.000118	CcSEcCtD
Haloperidol—Dermatitis—Prednisolone—hematologic cancer	1.77e-05	0.000118	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.77e-05	0.000118	CcSEcCtD
Haloperidol—Headache—Prednisolone—hematologic cancer	1.76e-05	0.000118	CcSEcCtD
Haloperidol—Vertigo—Epirubicin—hematologic cancer	1.76e-05	0.000117	CcSEcCtD
Haloperidol—Leukopenia—Epirubicin—hematologic cancer	1.75e-05	0.000117	CcSEcCtD
Haloperidol—Constipation—Prednisone—hematologic cancer	1.75e-05	0.000117	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—hematologic cancer	1.74e-05	0.000116	CcSEcCtD
Haloperidol—Confusional state—Methotrexate—hematologic cancer	1.72e-05	0.000115	CcSEcCtD
Haloperidol—Dizziness—Triamcinolone—hematologic cancer	1.71e-05	0.000114	CcSEcCtD
Haloperidol—Anaphylactic shock—Methotrexate—hematologic cancer	1.71e-05	0.000114	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—hematologic cancer	1.71e-05	0.000114	CcSEcCtD
Haloperidol—Convulsion—Epirubicin—hematologic cancer	1.7e-05	0.000113	CcSEcCtD
Haloperidol—Nausea—Etoposide—hematologic cancer	1.69e-05	0.000113	CcSEcCtD
Haloperidol—Hypertension—Epirubicin—hematologic cancer	1.69e-05	0.000113	CcSEcCtD
Haloperidol—Feeling abnormal—Prednisone—hematologic cancer	1.68e-05	0.000112	CcSEcCtD
Haloperidol—Nervous system disorder—Methotrexate—hematologic cancer	1.68e-05	0.000112	CcSEcCtD
Haloperidol—Anaemia—Doxorubicin—hematologic cancer	1.68e-05	0.000112	CcSEcCtD
Haloperidol—Thrombocytopenia—Methotrexate—hematologic cancer	1.67e-05	0.000112	CcSEcCtD
Haloperidol—Nausea—Prednisolone—hematologic cancer	1.67e-05	0.000111	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—hematologic cancer	1.67e-05	0.000111	CcSEcCtD
Haloperidol—Anxiety—Epirubicin—hematologic cancer	1.66e-05	0.000111	CcSEcCtD
Haloperidol—Pruritus—Dexamethasone—hematologic cancer	1.66e-05	0.000111	CcSEcCtD
Haloperidol—Pruritus—Betamethasone—hematologic cancer	1.66e-05	0.000111	CcSEcCtD
Haloperidol—Skin disorder—Methotrexate—hematologic cancer	1.66e-05	0.000111	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.66e-05	0.00011	CcSEcCtD
Haloperidol—Hyperhidrosis—Methotrexate—hematologic cancer	1.65e-05	0.00011	CcSEcCtD
Haloperidol—Vomiting—Triamcinolone—hematologic cancer	1.64e-05	0.00011	CcSEcCtD
Haloperidol—Rash—Triamcinolone—hematologic cancer	1.63e-05	0.000109	CcSEcCtD
Haloperidol—Dry mouth—Epirubicin—hematologic cancer	1.63e-05	0.000109	CcSEcCtD
Haloperidol—Dermatitis—Triamcinolone—hematologic cancer	1.63e-05	0.000109	CcSEcCtD
Haloperidol—Vertigo—Doxorubicin—hematologic cancer	1.63e-05	0.000109	CcSEcCtD
Haloperidol—Anorexia—Methotrexate—hematologic cancer	1.63e-05	0.000109	CcSEcCtD
Haloperidol—Urticaria—Prednisone—hematologic cancer	1.62e-05	0.000108	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—hematologic cancer	1.62e-05	0.000108	CcSEcCtD
Haloperidol—Headache—Triamcinolone—hematologic cancer	1.62e-05	0.000108	CcSEcCtD
Haloperidol—Body temperature increased—Prednisone—hematologic cancer	1.62e-05	0.000108	CcSEcCtD
Haloperidol—Confusional state—Epirubicin—hematologic cancer	1.61e-05	0.000107	CcSEcCtD
Haloperidol—Diarrhoea—Betamethasone—hematologic cancer	1.61e-05	0.000107	CcSEcCtD
Haloperidol—Diarrhoea—Dexamethasone—hematologic cancer	1.61e-05	0.000107	CcSEcCtD
Haloperidol—Anaphylactic shock—Epirubicin—hematologic cancer	1.6e-05	0.000107	CcSEcCtD
Haloperidol—Oedema—Epirubicin—hematologic cancer	1.6e-05	0.000107	CcSEcCtD
Haloperidol—Hypotension—Methotrexate—hematologic cancer	1.6e-05	0.000106	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—hematologic cancer	1.57e-05	0.000105	CcSEcCtD
Haloperidol—Nervous system disorder—Epirubicin—hematologic cancer	1.57e-05	0.000105	CcSEcCtD
Haloperidol—Thrombocytopenia—Epirubicin—hematologic cancer	1.57e-05	0.000104	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—hematologic cancer	1.56e-05	0.000104	CcSEcCtD
Haloperidol—Tachycardia—Epirubicin—hematologic cancer	1.56e-05	0.000104	CcSEcCtD
Haloperidol—Skin disorder—Epirubicin—hematologic cancer	1.55e-05	0.000104	CcSEcCtD
Haloperidol—Dizziness—Dexamethasone—hematologic cancer	1.55e-05	0.000103	CcSEcCtD
Haloperidol—Dizziness—Betamethasone—hematologic cancer	1.55e-05	0.000103	CcSEcCtD
Haloperidol—Hyperhidrosis—Epirubicin—hematologic cancer	1.55e-05	0.000103	CcSEcCtD
Haloperidol—Insomnia—Methotrexate—hematologic cancer	1.54e-05	0.000103	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—hematologic cancer	1.54e-05	0.000103	CcSEcCtD
Haloperidol—Nausea—Triamcinolone—hematologic cancer	1.54e-05	0.000102	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.53e-05	0.000102	CcSEcCtD
Haloperidol—Anorexia—Epirubicin—hematologic cancer	1.52e-05	0.000102	CcSEcCtD
Haloperidol—Dyspnoea—Methotrexate—hematologic cancer	1.52e-05	0.000102	CcSEcCtD
Haloperidol—Somnolence—Methotrexate—hematologic cancer	1.52e-05	0.000101	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—hematologic cancer	1.51e-05	0.000101	CcSEcCtD
Haloperidol—Hypersensitivity—Prednisone—hematologic cancer	1.51e-05	0.0001	CcSEcCtD
Haloperidol—Dyspepsia—Methotrexate—hematologic cancer	1.5e-05	0.0001	CcSEcCtD
Haloperidol—Hypotension—Epirubicin—hematologic cancer	1.49e-05	9.96e-05	CcSEcCtD
Haloperidol—Vomiting—Dexamethasone—hematologic cancer	1.49e-05	9.95e-05	CcSEcCtD
Haloperidol—Vomiting—Betamethasone—hematologic cancer	1.49e-05	9.95e-05	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—hematologic cancer	1.49e-05	9.95e-05	CcSEcCtD
Haloperidol—Decreased appetite—Methotrexate—hematologic cancer	1.48e-05	9.9e-05	CcSEcCtD
Haloperidol—Rash—Dexamethasone—hematologic cancer	1.48e-05	9.87e-05	CcSEcCtD
Haloperidol—Rash—Betamethasone—hematologic cancer	1.48e-05	9.87e-05	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—hematologic cancer	1.48e-05	9.86e-05	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—hematologic cancer	1.48e-05	9.86e-05	CcSEcCtD
Haloperidol—Dermatitis—Betamethasone—hematologic cancer	1.48e-05	9.86e-05	CcSEcCtD
Haloperidol—Dermatitis—Dexamethasone—hematologic cancer	1.48e-05	9.86e-05	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.47e-05	9.83e-05	CcSEcCtD
Haloperidol—Headache—Betamethasone—hematologic cancer	1.47e-05	9.8e-05	CcSEcCtD
Haloperidol—Headache—Dexamethasone—hematologic cancer	1.47e-05	9.8e-05	CcSEcCtD
Haloperidol—Nervous system disorder—Doxorubicin—hematologic cancer	1.45e-05	9.67e-05	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—hematologic cancer	1.45e-05	9.66e-05	CcSEcCtD
Haloperidol—Pruritus—Prednisone—hematologic cancer	1.45e-05	9.64e-05	CcSEcCtD
Haloperidol—Insomnia—Epirubicin—hematologic cancer	1.45e-05	9.64e-05	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—hematologic cancer	1.44e-05	9.63e-05	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—hematologic cancer	1.44e-05	9.58e-05	CcSEcCtD
Haloperidol—Hyperhidrosis—Doxorubicin—hematologic cancer	1.43e-05	9.54e-05	CcSEcCtD
Haloperidol—Dyspnoea—Epirubicin—hematologic cancer	1.43e-05	9.5e-05	CcSEcCtD
Haloperidol—Somnolence—Epirubicin—hematologic cancer	1.42e-05	9.48e-05	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—hematologic cancer	1.41e-05	9.4e-05	CcSEcCtD
Haloperidol—Feeling abnormal—Methotrexate—hematologic cancer	1.41e-05	9.39e-05	CcSEcCtD
Haloperidol—Dyspepsia—Epirubicin—hematologic cancer	1.41e-05	9.38e-05	CcSEcCtD
Haloperidol—Diarrhoea—Prednisone—hematologic cancer	1.4e-05	9.33e-05	CcSEcCtD
Haloperidol—Nausea—Betamethasone—hematologic cancer	1.39e-05	9.3e-05	CcSEcCtD
Haloperidol—Nausea—Dexamethasone—hematologic cancer	1.39e-05	9.3e-05	CcSEcCtD
Haloperidol—Decreased appetite—Epirubicin—hematologic cancer	1.39e-05	9.27e-05	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—hematologic cancer	1.38e-05	9.22e-05	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.38e-05	9.2e-05	CcSEcCtD
Haloperidol—Constipation—Epirubicin—hematologic cancer	1.37e-05	9.12e-05	CcSEcCtD
Haloperidol—Urticaria—Methotrexate—hematologic cancer	1.36e-05	9.05e-05	CcSEcCtD
Haloperidol—Dizziness—Prednisone—hematologic cancer	1.35e-05	9.01e-05	CcSEcCtD
Haloperidol—Body temperature increased—Methotrexate—hematologic cancer	1.35e-05	9e-05	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—hematologic cancer	1.34e-05	8.92e-05	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—hematologic cancer	1.32e-05	8.79e-05	CcSEcCtD
Haloperidol—Feeling abnormal—Epirubicin—hematologic cancer	1.32e-05	8.78e-05	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—hematologic cancer	1.31e-05	8.77e-05	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—hematologic cancer	1.3e-05	8.68e-05	CcSEcCtD
Haloperidol—Vomiting—Prednisone—hematologic cancer	1.3e-05	8.67e-05	CcSEcCtD
Haloperidol—Rash—Prednisone—hematologic cancer	1.29e-05	8.59e-05	CcSEcCtD
Haloperidol—Dermatitis—Prednisone—hematologic cancer	1.29e-05	8.59e-05	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—hematologic cancer	1.29e-05	8.57e-05	CcSEcCtD
Haloperidol—Headache—Prednisone—hematologic cancer	1.28e-05	8.54e-05	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.28e-05	8.52e-05	CcSEcCtD
Haloperidol—Urticaria—Epirubicin—hematologic cancer	1.27e-05	8.47e-05	CcSEcCtD
Haloperidol—Constipation—Doxorubicin—hematologic cancer	1.26e-05	8.43e-05	CcSEcCtD
Haloperidol—Body temperature increased—Epirubicin—hematologic cancer	1.26e-05	8.43e-05	CcSEcCtD
Haloperidol—Hypersensitivity—Methotrexate—hematologic cancer	1.26e-05	8.39e-05	CcSEcCtD
Haloperidol—Feeling abnormal—Doxorubicin—hematologic cancer	1.22e-05	8.13e-05	CcSEcCtD
Haloperidol—Nausea—Prednisone—hematologic cancer	1.21e-05	8.1e-05	CcSEcCtD
Haloperidol—Pruritus—Methotrexate—hematologic cancer	1.21e-05	8.06e-05	CcSEcCtD
Haloperidol—Hypersensitivity—Epirubicin—hematologic cancer	1.18e-05	7.85e-05	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—hematologic cancer	1.17e-05	7.84e-05	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—hematologic cancer	1.17e-05	7.8e-05	CcSEcCtD
Haloperidol—Diarrhoea—Methotrexate—hematologic cancer	1.17e-05	7.79e-05	CcSEcCtD
Haloperidol—Pruritus—Epirubicin—hematologic cancer	1.13e-05	7.54e-05	CcSEcCtD
Haloperidol—Dizziness—Methotrexate—hematologic cancer	1.13e-05	7.53e-05	CcSEcCtD
Haloperidol—Diarrhoea—Epirubicin—hematologic cancer	1.09e-05	7.29e-05	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—hematologic cancer	1.09e-05	7.27e-05	CcSEcCtD
Haloperidol—Vomiting—Methotrexate—hematologic cancer	1.09e-05	7.24e-05	CcSEcCtD
Haloperidol—Rash—Methotrexate—hematologic cancer	1.08e-05	7.18e-05	CcSEcCtD
Haloperidol—Dermatitis—Methotrexate—hematologic cancer	1.08e-05	7.18e-05	CcSEcCtD
Haloperidol—Headache—Methotrexate—hematologic cancer	1.07e-05	7.14e-05	CcSEcCtD
Haloperidol—Dizziness—Epirubicin—hematologic cancer	1.06e-05	7.05e-05	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—hematologic cancer	1.05e-05	6.98e-05	CcSEcCtD
Haloperidol—Vomiting—Epirubicin—hematologic cancer	1.02e-05	6.78e-05	CcSEcCtD
Haloperidol—Nausea—Methotrexate—hematologic cancer	1.01e-05	6.77e-05	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—hematologic cancer	1.01e-05	6.75e-05	CcSEcCtD
Haloperidol—Rash—Epirubicin—hematologic cancer	1.01e-05	6.72e-05	CcSEcCtD
Haloperidol—Dermatitis—Epirubicin—hematologic cancer	1.01e-05	6.72e-05	CcSEcCtD
Haloperidol—Headache—Epirubicin—hematologic cancer	1e-05	6.68e-05	CcSEcCtD
Haloperidol—Dizziness—Doxorubicin—hematologic cancer	9.78e-06	6.52e-05	CcSEcCtD
Haloperidol—Nausea—Epirubicin—hematologic cancer	9.49e-06	6.33e-05	CcSEcCtD
Haloperidol—Vomiting—Doxorubicin—hematologic cancer	9.4e-06	6.27e-05	CcSEcCtD
Haloperidol—Rash—Doxorubicin—hematologic cancer	9.33e-06	6.22e-05	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—hematologic cancer	9.32e-06	6.21e-05	CcSEcCtD
Haloperidol—Headache—Doxorubicin—hematologic cancer	9.27e-06	6.18e-05	CcSEcCtD
Haloperidol—Nausea—Doxorubicin—hematologic cancer	8.79e-06	5.86e-05	CcSEcCtD
Haloperidol—HTR2A—Signaling Pathways—FGF2—hematologic cancer	1.2e-06	1.59e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—FGF2—hematologic cancer	1.19e-06	1.58e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EP300—hematologic cancer	1.19e-06	1.58e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.19e-06	1.58e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MYC—hematologic cancer	1.19e-06	1.57e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TGFB1—hematologic cancer	1.19e-06	1.57e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ABCB1—hematologic cancer	1.18e-06	1.57e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3R1—hematologic cancer	1.18e-06	1.56e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3R1—hematologic cancer	1.18e-06	1.56e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CD—hematologic cancer	1.18e-06	1.56e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3R1—hematologic cancer	1.18e-06	1.56e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—SRC—hematologic cancer	1.18e-06	1.56e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MYC—hematologic cancer	1.17e-06	1.55e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TGFB1—hematologic cancer	1.17e-06	1.55e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—JAK2—hematologic cancer	1.17e-06	1.54e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ALB—hematologic cancer	1.16e-06	1.54e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—SRC—hematologic cancer	1.16e-06	1.54e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CD44—hematologic cancer	1.16e-06	1.53e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NQO1—hematologic cancer	1.16e-06	1.53e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NCOR1—hematologic cancer	1.15e-06	1.52e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTM1—hematologic cancer	1.15e-06	1.52e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.15e-06	1.52e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MAPK3—hematologic cancer	1.15e-06	1.52e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—JAK2—hematologic cancer	1.15e-06	1.52e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—JAK2—hematologic cancer	1.14e-06	1.52e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—hematologic cancer	1.14e-06	1.52e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—PIK3CA—hematologic cancer	1.14e-06	1.51e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MDM2—hematologic cancer	1.14e-06	1.51e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—STAT3—hematologic cancer	1.13e-06	1.5e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NRAS—hematologic cancer	1.13e-06	1.5e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—hematologic cancer	1.13e-06	1.5e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PIK3CA—hematologic cancer	1.12e-06	1.49e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PIK3CA—hematologic cancer	1.12e-06	1.49e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KRAS—hematologic cancer	1.12e-06	1.49e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MDM2—hematologic cancer	1.12e-06	1.48e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—STAT3—hematologic cancer	1.12e-06	1.48e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MDM2—hematologic cancer	1.12e-06	1.48e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MYC—hematologic cancer	1.12e-06	1.48e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NRAS—hematologic cancer	1.12e-06	1.48e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TGFB1—hematologic cancer	1.11e-06	1.48e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3R1—hematologic cancer	1.11e-06	1.47e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MTOR—hematologic cancer	1.11e-06	1.47e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CB—hematologic cancer	1.11e-06	1.47e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KRAS—hematologic cancer	1.1e-06	1.46e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.1e-06	1.45e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYCS—hematologic cancer	1.1e-06	1.45e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	1.09e-06	1.44e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MTOR—hematologic cancer	1.09e-06	1.44e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PIK3CA—hematologic cancer	1.09e-06	1.44e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.09e-06	1.44e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MTOR—hematologic cancer	1.09e-06	1.44e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CB—hematologic cancer	1.09e-06	1.44e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CB—hematologic cancer	1.09e-06	1.44e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MAPK3—hematologic cancer	1.08e-06	1.43e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KRAS—hematologic cancer	1.08e-06	1.43e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.07e-06	1.42e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MAPK3—hematologic cancer	1.07e-06	1.42e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—HRAS—hematologic cancer	1.06e-06	1.4e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MYC—hematologic cancer	1.05e-06	1.4e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TGFB1—hematologic cancer	1.05e-06	1.39e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.05e-06	1.39e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	1.04e-06	1.38e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1B—hematologic cancer	1.04e-06	1.38e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MYC—hematologic cancer	1.04e-06	1.38e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HRAS—hematologic cancer	1.04e-06	1.37e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TGFB1—hematologic cancer	1.04e-06	1.37e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KRAS—hematologic cancer	1.03e-06	1.37e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	1.03e-06	1.37e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	1.03e-06	1.36e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CB—hematologic cancer	1.03e-06	1.36e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	1.02e-06	1.35e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1B—hematologic cancer	1.02e-06	1.35e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CASP3—hematologic cancer	1.02e-06	1.35e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL2—hematologic cancer	1.02e-06	1.35e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.02e-06	1.35e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.02e-06	1.35e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL6—hematologic cancer	1.01e-06	1.34e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	1.01e-06	1.34e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—AKT1—hematologic cancer	1.01e-06	1.34e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	1.01e-06	1.34e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.01e-06	1.34e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CASP3—hematologic cancer	1e-06	1.33e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL2—hematologic cancer	1e-06	1.33e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CASP3—hematologic cancer	1e-06	1.32e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CG—hematologic cancer	9.99e-07	1.32e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL2—hematologic cancer	9.98e-07	1.32e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—hematologic cancer	9.97e-07	1.32e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL6—hematologic cancer	9.95e-07	1.32e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL6—hematologic cancer	9.93e-07	1.32e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PIK3CA—hematologic cancer	9.93e-07	1.32e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CREBBP—hematologic cancer	9.92e-07	1.31e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCND1—hematologic cancer	9.91e-07	1.31e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—JUN—hematologic cancer	9.89e-07	1.31e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—hematologic cancer	9.76e-07	1.29e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCND1—hematologic cancer	9.75e-07	1.29e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—JUN—hematologic cancer	9.73e-07	1.29e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCND1—hematologic cancer	9.73e-07	1.29e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KRAS—hematologic cancer	9.73e-07	1.29e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—JUN—hematologic cancer	9.71e-07	1.29e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTP1—hematologic cancer	9.66e-07	1.28e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CD—hematologic cancer	9.63e-07	1.28e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—hematologic cancer	9.61e-07	1.27e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KRAS—hematologic cancer	9.6e-07	1.27e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	9.59e-07	1.27e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTEN—hematologic cancer	9.57e-07	1.27e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HRAS—hematologic cancer	9.53e-07	1.26e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ALB—hematologic cancer	9.51e-07	1.26e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	9.48e-07	1.26e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	9.43e-07	1.25e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	9.41e-07	1.25e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTEN—hematologic cancer	9.41e-07	1.25e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CD—hematologic cancer	9.4e-07	1.25e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTEN—hematologic cancer	9.39e-07	1.24e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTEN—hematologic cancer	9.39e-07	1.24e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MAPK8—hematologic cancer	9.36e-07	1.24e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CREBBP—hematologic cancer	9.34e-07	1.24e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HRAS—hematologic cancer	9.34e-07	1.24e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AKT1—hematologic cancer	9.33e-07	1.24e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ALB—hematologic cancer	9.28e-07	1.23e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CREBBP—hematologic cancer	9.26e-07	1.23e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	9.21e-07	1.22e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MAPK8—hematologic cancer	9.19e-07	1.22e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HRAS—hematologic cancer	9.19e-07	1.22e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	9.18e-07	1.22e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—hematologic cancer	9.17e-07	1.21e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AKT1—hematologic cancer	9.16e-07	1.21e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PIK3CA—hematologic cancer	9.16e-07	1.21e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ABCB1—hematologic cancer	9.14e-07	1.21e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL6—hematologic cancer	9.13e-07	1.21e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EP300—hematologic cancer	9.12e-07	1.21e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3R1—hematologic cancer	9.1e-07	1.21e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EP300—hematologic cancer	8.98e-07	1.19e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EP300—hematologic cancer	8.96e-07	1.19e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.96e-07	1.19e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—EP300—hematologic cancer	8.95e-07	1.19e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	8.94e-07	1.18e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL6—hematologic cancer	8.93e-07	1.18e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—AKT1—hematologic cancer	8.9e-07	1.18e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3R1—hematologic cancer	8.88e-07	1.18e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NCOR1—hematologic cancer	8.87e-07	1.18e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTM1—hematologic cancer	8.87e-07	1.18e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SRC—hematologic cancer	8.87e-07	1.18e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTEN—hematologic cancer	8.87e-07	1.17e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CD—hematologic cancer	8.86e-07	1.17e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PIK3CA—hematologic cancer	8.82e-07	1.17e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL6—hematologic cancer	8.79e-07	1.16e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CD—hematologic cancer	8.78e-07	1.16e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HRAS—hematologic cancer	8.77e-07	1.16e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ALB—hematologic cancer	8.75e-07	1.16e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SRC—hematologic cancer	8.73e-07	1.16e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SRC—hematologic cancer	8.71e-07	1.15e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ALB—hematologic cancer	8.67e-07	1.15e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—hematologic cancer	8.65e-07	1.15e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—hematologic cancer	8.64e-07	1.14e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—STAT3—hematologic cancer	8.56e-07	1.13e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CG—hematologic cancer	8.54e-07	1.13e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NRAS—hematologic cancer	8.53e-07	1.13e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—hematologic cancer	8.53e-07	1.13e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	8.5e-07	1.13e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—hematologic cancer	8.48e-07	1.12e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—EP300—hematologic cancer	8.46e-07	1.12e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AKT1—hematologic cancer	8.42e-07	1.12e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—STAT3—hematologic cancer	8.42e-07	1.12e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—STAT3—hematologic cancer	8.4e-07	1.11e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NRAS—hematologic cancer	8.4e-07	1.11e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CB—hematologic cancer	8.4e-07	1.11e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL6—hematologic cancer	8.39e-07	1.11e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NRAS—hematologic cancer	8.38e-07	1.11e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3R1—hematologic cancer	8.37e-07	1.11e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3R1—hematologic cancer	8.29e-07	1.1e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HRAS—hematologic cancer	8.27e-07	1.1e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AKT1—hematologic cancer	8.24e-07	1.09e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CB—hematologic cancer	8.2e-07	1.09e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MAPK3—hematologic cancer	8.17e-07	1.08e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HRAS—hematologic cancer	8.16e-07	1.08e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AKT1—hematologic cancer	8.11e-07	1.07e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	8.04e-07	1.07e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MAPK3—hematologic cancer	8.03e-07	1.06e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MYC—hematologic cancer	7.95e-07	1.05e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TGFB1—hematologic cancer	7.93e-07	1.05e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CREBBP—hematologic cancer	7.92e-07	1.05e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL6—hematologic cancer	7.92e-07	1.05e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—MTHFR—hematologic cancer	7.84e-07	1.04e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MYC—hematologic cancer	7.82e-07	1.04e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL6—hematologic cancer	7.81e-07	1.03e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MYC—hematologic cancer	7.81e-07	1.03e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	7.8e-07	1.03e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TGFB1—hematologic cancer	7.79e-07	1.03e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AKT1—hematologic cancer	7.74e-07	1.03e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CB—hematologic cancer	7.72e-07	1.02e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CB—hematologic cancer	7.66e-07	1.01e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CD—hematologic cancer	7.51e-07	9.94e-06	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—AKT1—hematologic cancer	7.48e-07	9.91e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ALB—hematologic cancer	7.41e-07	9.82e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KRAS—hematologic cancer	7.35e-07	9.73e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AKT1—hematologic cancer	7.3e-07	9.67e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTEN—hematologic cancer	7.26e-07	9.61e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KRAS—hematologic cancer	7.23e-07	9.58e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KRAS—hematologic cancer	7.21e-07	9.56e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AKT1—hematologic cancer	7.2e-07	9.55e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3R1—hematologic cancer	7.09e-07	9.39e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTEN—hematologic cancer	7.08e-07	9.38e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—EP300—hematologic cancer	6.92e-07	9.17e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—EP300—hematologic cancer	6.75e-07	8.95e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	6.75e-07	8.94e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTEN—hematologic cancer	6.67e-07	8.84e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	6.64e-07	8.8e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	6.63e-07	8.78e-06	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CA—hematologic cancer	6.62e-07	8.77e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTEN—hematologic cancer	6.62e-07	8.77e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CG—hematologic cancer	6.59e-07	8.73e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CB—hematologic cancer	6.54e-07	8.67e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—hematologic cancer	6.53e-07	8.65e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—hematologic cancer	6.42e-07	8.51e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—hematologic cancer	6.41e-07	8.49e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—EP300—hematologic cancer	6.36e-07	8.43e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—EP300—hematologic cancer	6.31e-07	8.36e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CA—hematologic cancer	6.26e-07	8.29e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HRAS—hematologic cancer	6.24e-07	8.27e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HRAS—hematologic cancer	6.14e-07	8.14e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HRAS—hematologic cancer	6.13e-07	8.12e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CREBBP—hematologic cancer	6.11e-07	8.09e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL6—hematologic cancer	5.98e-07	7.92e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL6—hematologic cancer	5.88e-07	7.79e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL6—hematologic cancer	5.87e-07	7.77e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CD—hematologic cancer	5.79e-07	7.68e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ALB—hematologic cancer	5.72e-07	7.58e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTEN—hematologic cancer	5.65e-07	7.49e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AKT1—hematologic cancer	5.51e-07	7.3e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3R1—hematologic cancer	5.47e-07	7.25e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AKT1—hematologic cancer	5.42e-07	7.19e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AKT1—hematologic cancer	5.41e-07	7.17e-06	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—AKT1—hematologic cancer	5.41e-07	7.17e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—EP300—hematologic cancer	5.39e-07	7.14e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CA—hematologic cancer	5.12e-07	6.78e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—AKT1—hematologic cancer	5.11e-07	6.77e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CB—hematologic cancer	5.05e-07	6.69e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CA—hematologic cancer	5e-07	6.62e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CA—hematologic cancer	4.71e-07	6.24e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CA—hematologic cancer	4.67e-07	6.18e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTEN—hematologic cancer	4.36e-07	5.78e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AKT1—hematologic cancer	4.18e-07	5.54e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—EP300—hematologic cancer	4.16e-07	5.51e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AKT1—hematologic cancer	4.08e-07	5.41e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CA—hematologic cancer	3.99e-07	5.28e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AKT1—hematologic cancer	3.85e-07	5.1e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AKT1—hematologic cancer	3.81e-07	5.05e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AKT1—hematologic cancer	3.26e-07	4.32e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CA—hematologic cancer	3.08e-07	4.08e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKT1—hematologic cancer	2.51e-07	3.33e-06	CbGpPWpGaD
